Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway

Basic Research in Cardiology

Volumn 111, Issue 2, 2016, Pages 1-17

  Li, Chang Yi ^a   Zhou, Qing ^a   Yang, Ling Chao ^a   Chen, Yi He ^a   Hou, Jian Wen ^a   Guo, Kai ^a   Wang, Yue Peng ^a   Li, Yi Gang ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cardiac hypertrophy; Dual specificity phosphatases; Mitogen activated protein kinases; Signal transduction

Indexed keywords

ANGIOTENSIN II; DUAL SPECIFICITY PHOSPHATASE 14; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; PHOSPHATASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; DUAL SPECIFICITY PHOSPHATASE; DUSP14 PROTEIN, HUMAN; DUSP14 PROTEIN, MOUSE; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE;

ADENOVIRIDAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE LOSS; GENE OVEREXPRESSION; HEART DISEASE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CASE CONTROL STUDY; CELL CULTURE; ENZYMOLOGY; GENETICS; HEART FAILURE; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RAT;

ANGIOTENSIN II; ANIMALS; BASE SEQUENCE; CARDIOMEGALY; CASE-CONTROL STUDIES; CELLS, CULTURED; DUAL-SPECIFICITY PHOSPHATASES; HEART FAILURE; HEK293 CELLS; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; MOLECULAR SEQUENCE DATA; MYOCYTES, CARDIAC; RATS;

EID: 84958741519     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-016-0536-7     Document Type: Article

References (39)

1. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN (2002) Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci 99:907–912. doi:10.1073/pnas.231619298
2. Biesemann N, Mendler L, Kostin S, Wietelmann A, Borchardt T, Braun T (2015) Myostatin induces interstitial fibrosis in the heart via TAK1 and p38. Cell Tissue Res. doi:10.1007/s00441-015-2139-2
3. Bisserier M, Berthouze-Duquesnes M, Breckler M, Tortosa F, Fazal L, de Regibus A, Laurent AC, Varin A, Lucas A, Branchereau M, Marck P, Schickel JN, Delomenie C, Cazorla O, Soulas-Sprauel P, Crozatier B, Morel E, Heymes C, Lezoualc’h F (2015) Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling. Circulation 131:390–400. doi:10.1161/CIRCULATIONAHA.114.010686(discussion 400)
4. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, Hewett TE, Molkentin JD (2003) Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 111:1475–1486. doi:10.1172/JCI17295
5. Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8:30–41. doi:10.1038/nrcardio.2010.165
6. de Simone G, Gottdiener JS, Chinali M, Maurer MS (2008) Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J 29:741–747. doi:10.1093/eurheartj/ehm605
7. Drazner MH (2011) The progression of hypertensive heart disease. Circulation 123:327–334. doi:10.1161/CIRCULATIONAHA.108.845792
8. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS (2004) Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 43:2207–2215. doi:10.1016/j.jacc.2003.11.064
9. Garrington TP, Johnson GL (1999) Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11:211–218. doi:10.1016/S0955-0674(99)80028-3
10. Greenberg B (2015) CUPID 2: a phase 2b trial investigating the efficacy and safety of the intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure. 917—Hot Line V—Heart Failure, London
11. Hajjar RJ (2013) Potential of gene therapy as a treatment for heart failure. J Clin Invest 123:53–61. doi:10.1172/JCI62837
12. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600. doi:10.1038/nrm1983
13. Hill JA, Olson EN (2008) Cardiac plasticity. N Engl J Med 358:1370–1380. doi:10.1056/NEJMra072139
14. Jeffrey KL, Camps M, Rommel C, Mackay CR (2007) Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6:391–403. doi:10.1038/nrd2289
15. Jiang DS, Wei X, Zhang XF, Liu Y, Zhang Y, Chen K, Gao L, Zhou H, Zhu XH, Liu PP, Bond Lau W, Ma X, Zou Y, Zhang XD, Fan GC, Li H (2014) IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nat Commun 5:3303. doi:10.1038/ncomms4303
16. Kinugawa K, Jeong MY, Bristow MR, Long CS (2005) Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor α1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase. Mol Endocrinol 19:1618–1628. doi:10.1210/me.2004-0503
17. Klinger S, Poussin C, Debril MB, Dolci W, Halban PA, Thorens B (2008) Increasing GLP-1-induced β-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-α and DUSP14. Diabetes 57:584–593. doi:10.2337/db07-1414
18. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA (2011) Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest 121:2301–2312. doi:10.1172/JCI44824
19. Li H, He C, Feng J, Zhang Y, Tang Q, Bian Z, Bai X, Zhou H, Jiang H, Heximer SP, Qin M, Huang H, Liu PP, Huang C (2010) Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci 107:13818–13823. doi:10.1073/pnas.1008397107
20. Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD (2003) c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin–NFAT signaling. EMBO J 22:5079–5089. doi:10.1093/emboj/cdg474
21. Lorell BH, Carabello BA (2000) Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102:470–479
22. Marie-Claire C, Benturquia N, Lundqvist A, Courtin C, Noble F (2008) Characteristics of dual specificity phosphatases mRNA regulation by 3,4-methylenedioxymethamphetamine acute treatment in mice striatum. Brain Res 1239:42–48. doi:10.1016/j.brainres.2008.08.050
23. Marti F, Krause A, Post NH, Lyddane C, Dupont B, Sadelain M, King PD (2001) Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6. J Immunol 166:197–206
24. Matsumoto-Ida M, Takimoto Y, Aoyama T, Akao M, Takeda T, Kita T (2006) Activation of TGF-beta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 290:H709–H715. doi:10.1152/ajpheart.00186.2005
25. Minamino T, Yujiri T, Terada N, Taffet GE, Michael LH, Johnson GL, Schneider MD (2002) MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci 99:3866–3871. doi:10.1073/pnas.062453699
26. Patterson KI, Brummer T, O’Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475–489
27. Qin W, Du N, Zhang L, Wu X, Hu Y, Li X, Shen N, Li Y, Yang B, Xu C, Fang Z, Lu Y, Zhang Y, Du Z (2014) Genistein alleviates pressure overload-induced cardiac dysfunction and interstitial fibrosis in mice. Br J Pharmacol. doi:10.1111/bph.13002
28. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J Jr, Chien KR (1991) Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci 88:8277–8281
29. Rose BA, Force T, Wang Y (2010) Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 90:1507–1546. doi:10.1152/physrev.00054.2009
30. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, Dorn GW 2nd, Liao JK (2007) Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 115:3197–3204. doi:10.1161/CIRCULATIONAHA.106.657981
31. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, Yamada G, Akira S, Matsumoto K, Ghosh S (2005) TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 19:2668–2681. doi:10.1101/gad.1360605
32. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J (2012) TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148:639–650. doi:10.1016/j.cell.2011.12.033
33. Tanaka K, Honda M, Takabatake T (2001) Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 37:676–685. doi:10.1016/S0735-1097(00)01123-2
34. Villar AV, Garcia R, Llano M, Cobo M, Merino D, Lantero A, Tramullas M, Hurle JM, Hurle MA, Nistal JF (2013) BAMBI (BMP and activin membrane-bound inhibitor) protects the murine heart from pressure-overload biomechanical stress by restraining TGF-β signaling. Biochim Biophys Acta 1832:323–335. doi:10.1016/j.bbadis.2012.11.007
35. Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, Vernallis AB, Heath JK, Pennica D, Wood WI, Chien KR (1996) Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem 271:9535–9545
36. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K (1995) Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270:2008–2011
37. Yang CY, Li JP, Chiu LL, Lan JL, Chen DY, Chuang HC, Huang CY, Tan TH (2014) Dual-specificity phosphatase 14 (DUSP14/MKP6) negatively regulates TCR signaling by inhibiting TAB1 activation. J Immunol 192:1547–1557. doi:10.4049/jimmunol.1300989
38. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, Schneider MD (2000) TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6:556–563. doi:10.1038/75037
39. Zheng H, Li Q, Chen R, Zhang J, Ran Y, He X, Li S, Shu HB (2013) The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor- and interleukin-1-induced nuclear factor-κB activation by dephosphorylating the protein kinase TAK1. J Biol Chem 288:819–825. doi:10.1074/jbc.M112.412643